Results you can trust
The first and only FDA-approved and
CE-IVD marked PD-L1 test for use in both
non-squamous NSCLC and melanoma.
PD-L1 IHC 28-8 pharmDx training now available for NSCLC and Melanoma
Learn how to evaluate PD-L1 expression using PD-L1 IHC 28-8 pharmDx.
New Dako Omnis RTU antibodies
Introduction of 16 new high quality FLEX RTU antibodies for Dako Omnis.
See our solutions within pathology, next generation sequencing and molecular cancer research.
2016 Product Catalog
The 2016 Pathology Product Catalog is now available for download.
Events and Congresses
Meet us at congresses and events around the world.